Sfoglia per AUTORE
LINARDOU H
Collezione AOU San Luigi di Orbassano

  

Items : 4

Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary. in Future oncology (London, England) / Future Oncol. 2025 Mar 24:1-12. doi: 10.1080/14796694.2025.2474789.
2025
AOU San Luigi di Orbassano

de Langen AJ; Johnson ML; Mazieres J; Dingemans AC; Mountzios G; Pless M; Wolf J; Schuler M; Lena H; Skoulidis F; Yoneshima Y; Kim SW; Linardou H; Novello S; van der Wekken AJ; Chen Y; Peters S; Felip E; Solomon BJ; Ramalingam SS; Dooms C; Lindsay CR; Ferreira CG; Blais N; Obiozor CC; Wang Y; Mehta B; Varrieur T; Ngarmchamnanrith G; et alii...

Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2024 Oct;196:107921. doi: 10.1016/j.lungcan.2024.107921. Epub 2024 Aug 6.
2024
AOU San Luigi di Orbassano

Waterhouse DM; Rothschild S; Dooms C; Mennecier B; Bozorgmehr F; Majem M; van den Heuvel MH; Linardou H; Chul Cho B; Roberts-Thomson R; Tanaka K; Blais N; Schvartsman G; Holmskov Hansen K; Chmielewska I; Forster MD; Giannopoulou C; Stollenwerk B; Obiozor CC; Wang Y; Novello S;

Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA). in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02529-2. doi: 10.1016/j.jtho.2024.12.010.
2024
ASL Cuneo 2
ASL Asti
AOU San Luigi di Orbassano

Novello S; Scagliotti G; Righi L; Vallone S; Malapelle U; Volante M; Giannarelli D; Mohorcic K; Meoni G; Scotti V; Linardou H; Bettini AC; Ramizi KM; Secen N; Comanescu A; Felip E; Paz-Ares L; Pignataro D; Araujo A; Barbieri V; Mazilu L; Buffoni L; Taveggia PA; Simionato F; Roca E; Sini C; Tabbò F; Reale ML; Zambelli V; et alii...

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. in Lancet (London, England) / Lancet. 2023 Mar 4;401(10378):733-746. doi: 10.1016/S0140-6736(23)00221-0. Epub 2023 Feb 7.
2023
AOU San Luigi di Orbassano

de Langen AJ; Johnson ML; Mazieres J; Dingemans AC; Mountzios G; Pless M; Wolf J; Schuler M; Lena H; Skoulidis F; Yoneshima Y; Kim SW; Linardou H; Novello S; van der Wekken AJ; Chen Y; Peters S; Felip E; Solomon BJ; Ramalingam SS; Dooms C; Lindsay CR; Ferreira CG; Blais N; Obiozor CC; Wang Y; Mehta B; Varrieur T; Ngarmchamnanrith G; et alii...